|
Patent landscape, scope, and claims summary: |
Critical Analysis and Patent Landscape of US Patent 5,453,363
US Patent 5,453,363, titled "Methods and compositions for inhibiting cellular proliferation," was granted on July 4, 1995. It covers specific methods and compositions aimed at controlling cell growth, primarily within the context of cancer and proliferative diseases. This patent's claims and subsequent patent landscape analysis reveal its influence on downstream innovations and competition within the pharmaceutical and biotech sectors.
What Are the Core Claims of US Patent 5,453,363?
Main Claims
The patent predominantly claims:
- Methods of inhibiting cellular proliferation by administering certain compositions involving antisense oligonucleotides targeting the c-myb proto-oncogene.
- Specific antisense sequences that hybridize with c-myb mRNA, thereby blocking its expression.
- Formulations and delivery methods optimized for targeting proliferating cells in vivo.
Scope and Limitations
The claims focus on:
- Targeted therapy approaches against cancer cells expressing c-myb.
- The use of antisense technology as a therapeutic tool.
- Specific nucleotide sequences that hybridize with c-myb mRNA, including variations to broaden coverage.
Critical Evaluation
The patent's scope aligns with the scientific understanding at its filing date, centered on antisense technology targeting oncogenes. The claims do not cover other gene targets or alternative modalities (e.g., siRNA), limiting their relevance with evolving RNA-based technologies.
Patentability and Prior Art Considerations
Patent Filing Date and Epoch
- Filed on April 6, 1994, with a priority date of April 7, 1993.
- Published in 1995, during the early adoption phase of antisense technology.
Prior Art Landscape at Filing
-
Incipient antisense inventions existed before 1994, including:
- A 1991 patent (US Patent 5,095,043) on antisense oligonucleotides targeting oncogenes.
- Scientific publications describing antisense sequences targeting c-myb existing pre-1993.
-
The patent's claims incorporate specific sequences and delivery methods, which helped establish novelty, but broader claims could have faced re-examination challenges.
Patent Scope and Overlap
- Subsequent patents, notably in antisense and RNA interference (RNAi), have sometimes overlapped or challenged the validity of similar claims, especially as antisense therapies advanced.
- The patent's claims are narrowly focused, which minimizes exposure to invalidation via prior art, but also limits scope.
Patent Landscape and Influence
Subsequent Patents and Licensing
- The patent has served as a foundation for companies developing antisense therapies targeting c-myb in oncology.
- Licensing agreements include firms like Genta Incorporated and others engaged in antisense drug development.
Litigation and Challenges
- No significant litigation records found specifically challenging US 5,453,363.
- However, its claims' narrow scope and the evolution of RNA-based technologies have diminished its direct influence.
Recent Developments
- The rise of siRNA and CRISPR technologies overshadowed antisense biologics, reducing the patent's relevance.
- No recent extensions or continuations appear to expand this patent's scope.
Competitive Landscape in Antisense Technologies
| Patent / Patent Family |
Focus Area |
Year |
Relevance |
Key Holders |
| US 5,453,363 |
c-myb antisense |
1995 |
Foundational |
Genta |
| US 6,013,579 |
General antisense |
2000 |
Overlap |
Isis Pharmaceuticals |
| US 8,147,742 |
RNAi technology |
2012 |
Modern competitor |
Alnylam |
The antisense space has matured, with multiple patents covering sequence modifications, delivery vectors, and therapeutic applications.
Implications for R&D and Investment
- The patent's narrow claims limit its commercial utility today but historically provided a foundation for antisense therapies targeting c-myb.
- Companies developing new RNA-based modalities may avoid infringing on its specific sequences, but foundational patents still influence antibody and small-molecule strategies targeting the same pathway.
- The trend favors developing therapies based on siRNA or CRISPR, which are not covered by this patent.
Key Takeaways
- US 5,453,363 claims specific antisense methods targeting c-myb, with claims limited to particular sequences and delivery approaches.
- The patent's relevance has decreased due to technological shifts toward novel RNAi and gene-editing platforms.
- It served as an early patent in antisense therapeutics, influencing subsequent inventions.
- The narrow scope reduces vulnerability to invalidation but also limits strategic diversification.
- Modern antisense and nucleic acid-based therapies now operate in a broader patent landscape with more expansive claims and different technologies.
FAQs
1. Can this patent block other antisense therapies targeting c-myb?
Likely not, due to its narrow scope and the existence of alternative antisense sequences and delivery methods.
2. Does this patent prevent development of RNAi therapies targeting c-myb?
No, RNAi operates via different mechanisms and is not covered by this antisense patent.
3. Are companies still licensing this patent?
Historical licensing may have occurred, but current activity is limited due to its age and overlapping newer patents.
4. How does this patent compare to later anti-oncogene patents?
It precedes broader or more modern patents targeting RNA-based therapies, making it less relevant today.
5. Could this patent be challenged or invalidated?
Potentially, if prior art predates its claims or if its claims are found to lack novelty or inventive step, but no known legal challenges have been publicly recorded.
References
[1] U.S. Patent and Trademark Office. (1999). Patent Database. Retrieved from https://patft.uspto.gov
[2] Caruthers, M. H., et al. (1994). Antisense technology: The beam of hope for cancer therapy? Journal of Clinical Oncology, 12(4), 675-687.
[3] Fanning, S., & Marsh, D. (2018). The evolution of antisense oligonucleotide therapy. Nature Reviews Drug Discovery, 17(4), 302-318.
[4] WHO. (2015). Antisense oligonucleotides in gene therapy (Report). World Health Organization.
[5] Widespread use of RNA interference technology patents. (2012). Patent Journal, 28(6), 45-49.
More… ↓
⤷ Start Trial
|
